| 前收市價 | 55.43 |
| 開市 | 56.40 |
| 買盤 | 44.50 |
| 賣出價 | 49.50 |
| 拍板 | 460.00 |
| 到期日 | 2025-12-19 |
| 今日波幅 | 55.20 - 56.40 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 9 |
ZacksArgenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Investor's Business DailyArgenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.
ZacksFDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
